Price$11.10-0.75 (-6.32%)
01:30 PM03:30 PM
News · 26 weeks48-73%
2025-12-142026-06-07
Mix2490d
- SEC Filings9(38%)
- Insider8(33%)
- Other6(25%)
- Analyst1(4%)
Latest news
25 items- PRBiohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and ImmunomodulationBHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders First-in-human study initiated with dose escalation ongoing; preliminary data in healthy participants demonstrates favorable pharmacokinetics supporting convenient, once-daily dosing and well a tolerated profile at projected therapeutic exposuresPenetrates blood-brain barrier and reverses metabolic dysfunction with 3-fold improvement in glucose utilization in human, whole brain model (Bexorg BrainEx platform, physiologically reactivated brains from human donors); preferential metabolic rescue in Al
- SECBiohaven Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- PRBiohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA NephropathyBHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TSHR-IgG1exceeding >80% over the 12-week study.Participants with Graves' overt hyperthyroidism, confirmed by elevated baseline thyroid tests despite being treated with anti-thyroid drug therapy (ATD), experienced normalization of thyroid hormones within weeks; T4 normalization occurring at a median of 3 weeks and T3 at a median of 5 weeks after the first administration of BHV-1300.These preliminary patient data from an ongoing Phase 1b study highlight deep lowering of TSHR-IgG1 with BHV-1300 as a
- PRBiohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability ProfileIn a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakalim 75 mg once-daily treatment group vs. 47 days in the placebo group, representing a 3-fold prolongation.In an ongoing open-label extension (OLE) study in focal epilepsy, an updated data analysis shows 54% of patients with focal epilepsy on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency over any consecutive six months of open-label treatment compared to pre-randomization baseline.A six-month update of opakalim compassionate use treatment in a Kv7-activation dependent pat
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)
- SECBiohaven Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form 424B5 filed by Biohaven Ltd.424B5 - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form S-3ASR filed by Biohaven Ltd.S-3ASR - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form 10-Q filed by Biohaven Ltd.10-Q - Biohaven Ltd. (0001935979) (Filer)
- SECBiohaven Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Biohaven Ltd. (0001935979) (Filer)
- SECBiohaven Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Biohaven Ltd. (0001935979) (Filer)
- PRBiohaven Reports Recent Business Developments and First Quarter 2026 Financial ResultsBiohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026.Advancement of high-value, late-stage priority programs:Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026.TRAP™ and MoDE™ Degraders Advancing to Pivotal TrialsPivotal trials in both IgA nephropathy (IgAN) with Gd-IgA1 TRAP degrader, BHV-1400, and Graves' disease with IgG MoDE degrader, BHV-1300, expected to initiate by mid-year.Sustained progress acr
- INSIDERSEC Form 4 filed by Director Mehta Kishan4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Bailey Gregory4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Heffernan Michael Thomas4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Antonijevic Irina4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Childs John W4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Hugin Robert J4 - Biohaven Ltd. (0001935979) (Issuer)
- INSIDERSEC Form 4 filed by Director Gregory Julia P4 - Biohaven Ltd. (0001935979) (Issuer)
- ANALYSTCanaccord Genuity initiated coverage on Biohaven with a new price targetCanaccord Genuity initiated coverage of Biohaven with a rating of Buy and set a new price target of $21.00
- INSIDERSEC Form 4 filed by Mehta Kishan4 - Biohaven Ltd. (0001935979) (Issuer)
- PRBiohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes EnrollmentPhase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026.Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.In previous clinical studies, taldefgrobep produced meaningful reductions in fat mass while increasing lean muscle mass in healthy adults and other non-obese populations; it has also demonstrated a highly favorable safety and tolerability profile in more than 700 trial participants.In nonclinical studi
- SECSEC Form DEFA14A filed by Biohaven Ltd.DEFA14A - Biohaven Ltd. (0001935979) (Filer)
- SECSEC Form DEF 14A filed by Biohaven Ltd.DEF 14A - Biohaven Ltd. (0001935979) (Filer)
- INSIDERAmendment: Director Childs John W bought $864,115 worth of shares (28,400 units at $30.43) (SEC Form 4)4/A - Biohaven Ltd. (0001935979) (Issuer)
BHVN FAQ
7 questionsWhat does Biohaven Ltd. do?
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole...Where does BHVN stock trade?
Biohaven Ltd. (BHVN) is listed on NYSE.What sector and industry is BHVN in?
Biohaven Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Biohaven Ltd. go public?
Biohaven Ltd. (BHVN) completed its IPO in 2022.What are analysts saying about BHVN?
Biohaven Ltd. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $2100.00 price target on 2026-04-13. Recent price targets range from $900.00 to $2800.00.What companies are similar to BHVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BHVN side-by-side with any of them on Quantisnow.How can I track BHVN on Quantisnow?
Quantisnow aggregates Biohaven Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BHVN to receive live email and push alerts on every new disclosure.